An interventional study of Dry needling and Botulinium Toxin-A in Myofascial Pain - Dysfunction Syndrome of TMJ and Bruxism, sponsored by Saglik Bilimleri Universitesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Saglik Bilimleri Universitesi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Temporomandibular Joint Disorders with a site in Turkey — 27 open to participants now, 28 under way, none of them phase 3. Temporomandibular Joint Disorders · Turkey.
Among the 151 studies in Temporomandibular Joint Disorders with a site in Turkey, this one is the 8th largest by enrollment of the 81 interventional ones that give a count, is one of 16 that started in 2021, is one of 77 with no phase, and was the 151st registered.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →27 of the 151 studies in Temporomandibular Joint Disorders with a site in Turkey are open now. Recruiting first, the newest first:
Mustafa Kemal University · Sites in Turkey
Ages 35–75 · Healthy volunteers
sevilay seda bas · Sites in Turkey
Ages 18–55
Yuzuncu Yil University · Sites in Turkey
Ages 18–65
Uşak University · Sites in Turkey
Ages 18–65
Recep Tayyip Erdogan University · Sites in Turkey
Ages 18+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 45 across 415 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 45 across the 81 interventional studies, 78 across the 70 observational. Of the 115 that completed or were terminated, 4 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 151 has an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi is the lead sponsor of 456 studies on the registry; 139 are open to participants now.
Saglik Bilimleri Universitesi has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Temporomandibular Joint Disorders with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577687Yuzuncu Yil UniversityEffect of Emg-Biofeedback and Multimodal Exercise on Temporomandibular Joint Dysfunction | 2026-12-15 |
| NCT07850674Mustafa Kemal UniversitySpinal Mobility, Rigidity, and Kinesiophobia in PD and TMD | 2026-12-23 |
| NCT07576582Uşak UniversityPeloid Therapy in Temporomandibular Joint Dysfunction | 2027-01-01 |
| NCT07791173Zeynep Serra KalkanEvaluation of Temporomandibular Disorders During Pregnancy | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 151 studies in Temporomandibular Joint Disorders with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compared three treatments for myofascial pain in adults with clinical features of bruxism, such as tooth clenching or grinding. Myofascial pain is pain arising from muscles and sensitive areas within them.
Ninety adults aged 18-60 years were randomly assigned to one of three groups: dry needling, botulinum toxin type A injections, or an occlusal splint worn at night together with medication. Dry needling involved inserting thin needles into sensitive points in the masseter muscles. Botulinum toxin injections were administered into the masseter muscles on both sides. The splint group received tizanidine and paracetamol for one month.
The study assessed pain at rest and during jaw function, sensitivity to pressure, and mouth opening. Assessments were performed before treatment and at one day, one week, and one month after treatment. The purpose was to compare the short-term effects of these three treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intra-articular or degenerative temporomandibular disorders.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Thirty participants received a single session of dry needling targeting two or three active trigger points in each masseter muscle bilaterally. Sterile, single-use acupuncture needles (0.25 × 25 mm) were inserted approximately 5 mm deep, briefly manipulated, and retained for 20 minutes.
Procedure: Dry needling
Thirty participants received a custom-made maxillary occlusal splint combined with medication for one month. Splints were fabricated from 3-mm-thick polyvinyl acetate-polyethylene copolymer sheets using a vacuum-forming technique and individually fitted and adjusted. Participants were instructed to wear the splint every night for one month and take oral tizanidine 2 mg every 12 hours and paracetamol 500 mg every 12 hours for the same period.
Device: Occlusal Splint · Drug: TiZANidine 2 MG Oral Capsule · Drug: Paracetamol (500 mg) tablets
Thirty participants received a single session of botulinum toxin type A injections into both masseter muscles. A 100-unit vial was reconstituted with 2.5 mL of sterile 0.9% saline. Each masseter received 20 units distributed across three injection sites, for a total dose of 40 units per participant. Injections were administered with the needle inserted at approximately 45 degrees to the skin surface.
Drug: Botulinium Toxin-A
A single session of bilateral masseter dry needling was performed, targeting two or three active trigger points per muscle. Sterile, single-use acupuncture needles measuring 0.25 × 25 mm were inserted approximately 5 mm deep. Needles were briefly manipulated using rapid in-and-out movements and redirected within the trigger point region, then retained for 20 minutes.
Botulinum toxin type A (Botox, Allergan) was administered into both masseter muscles during a single session. A 100-unit vial was reconstituted with 2.5 mL of sterile 0.9% saline. Each masseter received 20 units distributed across three injection sites, for a total dose of 40 units per participant. The needle was inserted at approximately 45 degrees to the skin surface.
A custom-made maxillary occlusal splint was fabricated from a 3-mm-thick polyvinyl acetate-polyethylene copolymer sheet using a vacuum-forming technique. Each splint was individually fitted and adjusted intraorally. Participants were instructed to wear the splint every night for one month.
Tizanidine 2 mg was administered orally every 12 hours for one month as adjunctive pharmacotherapy in the occlusal splint group.
Paracetamol 500 mg was administered orally every 12 hours for one month as adjunctive pharmacotherapy in the occlusal splint group.
Pain Intensity at Rest
Pain intensity at rest was assessed using a 0-10 visual analog scale (VAS), where 0 indicated no pain and 10 indicated the worst imaginable pain. Lower scores indicate less pain.
Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.
Pain Intensity During Function
Pain intensity during jaw function was assessed using a 0-10 visual analog scale (VAS), where 0 indicated no pain and 10 indicated the worst imaginable pain. Lower scores indicate less pain.
Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.
Pressure Pain Threshold
Pressure pain threshold was measured in kg/cm² using a pressure algometer over the identified masseter trigger point. Pressure was applied perpendicular to the skin and increased at approximately 1 kg/cm² per second until pressure first became painful. Higher values indicate a higher pressure pain threshold.
Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.
Maximum Pain-Free Mouth Opening
Maximum pain-free mouth opening was measured as the interincisal distance in millimeters using a millimetric ruler. Participants opened their mouth until pain was first perceived. Greater distances indicate greater pain-free mouth opening.
Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.
Maximum Mouth Opening With Pain
Maximum mouth opening with pain was measured as the interincisal distance in millimeters using a millimetric ruler. Participants opened their mouth as far as possible despite the onset of pain. Greater distances indicate greater maximum mouth opening.
Time frame: Baseline (before treatment), Day 1, Week 1, and Month 1 after treatment.
Plan to share: No — There is currently no plan to share individual participant data with other researchers.
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in Oct 2022, 17 months.
Of 242 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's 17 months is above that.
Counting every sponsor, half of 246 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →
Saglik Bilimleri Universitesi →